Endometrial carcinomas are associated with which biomarker?

• A. ER/PR
• B. KRAS
• C. EGFR
• D. BRAF

Answer: (A)

Hormone receptor status is the key concept here. Endometrial carcinomas, especially the common endometrioid type, often express estrogen receptor and progesterone receptor. Detecting these receptors (ER and PR) helps classify the tumor and has practical implications: ER/PR-positive cancers are more likely to respond to hormonal therapies such as progestins and often indicate a different, typically less aggressive behavior than ER/PR-negative tumors. While other genes like KRAS, EGFR, or BRAF can be altered in various cancers, they are not the characteristic biomarker used to define or guide treatment for endometrial carcinoma. Therefore, ER/PR positivity is the biomarker most associated with endometrial carcinomas.